Holen Sie sich die Stockscreener-App
4.16
0.00%
0.00
Handel nachbörslich:
4.18
0.02
+0.48%
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
Most US states OK Medicaid pilot for sickle cell gene therapies - The Boston Globe
Press Release Distribution & PR Platform - ACCESS Newswire
Gene Therapy For Rare Disease Market Set to Witness Significant - openPR.com
Drug and Gene Delivery Devices Market Future Business - openPR.com
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline - Yahoo Finance
bluebird bio opts to stay with Carlyle/SK takeover offer - The Pharma Letter
Bluebird says Ayrmid missed deadline for rival takeover bid - BioPharma Dive
bluebird bio's board opts for sale to U.S. investment firms - The Business Journals
Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid - marketscreener.com
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer - BioSpace
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird - Endpoints News
bluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's Uncertaint - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - BioSpace
Bluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock Fell - Nasdaq
Bluebird bio shares fall amid acquisition woes - Investing.com Australia
Bluebird bio shares fall amid acquisition woes By Investing.com - Investing.com Canada
Tesla, Cal-Maine Foods, Bluebird Bio - TradingView
Bluebird Bio falls after Ayrmid fails to give binding offer - TradingView
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9% - MSN
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquis - GuruFocus
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquisition Deal | BLUE Stock News - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement | BLUE Stock News - GuruFocus
Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement - marketscreener.com
bluebird bio backs Carlyle and SK Capital takeover bid - Investing.com
Gene Therapy Market Insights 2025Trends, Growth Forecast & - openPR.com
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
Sickle Cell Disease Treatment Market to Hit $7.04 Billion By 2032 - openPR.com
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire
Biotechnology Company Grants Commercial License for Cell Manufacturing Platform Use to Advance SCD Therapy - Docwire News
Companies team up to support sickle cell gene therapy Lyfgenia - Sickle Cell Disease News
bluebird bio, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Gene Therapy Market Demand, Growth and Future Scope 2025-2032 | - openPR.com
Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking - Benzinga
Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener
Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire
BlueBird Shares Are Up Today: What's Going On? - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps - Benzinga
Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq
bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com
Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView
Bluebird bio receives non-binding bid for up to $110.5 million - MSN
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha
bluebird bio confirms rival takeover bid - The Pharma Letter
Bluebird Bio: A $110.5 Million Bid and the Future of Gene Therapy - AInvest
Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premiu - GuruFocus
New suitor emerges for struggling bluebird bio - FirstWord Pharma
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):